BioSpace News Archive

Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented preliminary data from its lead investigational product candidate, FYARRO™

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced that it has granted equity awards to six employees, none of whom are executive officers, as an inducement for them to accept employment with Surgalign, and representing the right to purchase or receive, in the aggregate, up to 179,667 shares of Surgalign common stock.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel (G+A) in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDA), at the American Society of Clinical Oncology (ASCO) Annual Meeting.

- Updated Data From ARTISTRY Clinical Program Highlight Anti-Tumor Activity as Monotherapy and in Combination With Pembrolizumab - - Data Support Advancement of Regulatory Strategy in Cancers With High Unmet Need - - Company to Host Investor Webcast Today at 4:00 p.m. ET -

Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021,

Diaceutics PLC, the diagnostic commercialisation company, today announces the acceptance of an abstract for a poster discussion presentation, discussing the impact of COVID-19 on cancer diagnosis, at the prestigious 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.

Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a research and development biotechnology company, today announced two abstract presentations of the Company’s lead product candidate, TACH101, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. ASCO is being held virtually from June 4-8, 2021.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 3:50 P.M. Eastern Time.

Immune Therapeutics Inc. (OTC-PINK: IMUN) (the “Company”) announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.